Literature DB >> 8982709

Tramadol, M1 metabolite and enantiomer affinities for cloned human opioid receptors expressed in transfected HN9.10 neuroblastoma cells.

J Lai1, S W Ma, F Porreca, R B Raffa.   

Abstract

Tramadol hydrochloride is a centrally acting synthetic analgesic in widespread clinical use. Despite different degrees of opioid-like characteristics in preclinical tests, it is characterized by lack of full naloxone reversibility or naloxone-precipitated withdrawal in humans. To investigate this apparent discrepancy, the present study measured the affinity of tramadol (and its enantiomers) and an active O-desmethyl metabolite (M1) (and its enantiomers) to cloned human opioid receptors of the mu, delta and kappa type stably expressed in HN9.10 neuroblastoma cells. At mu sites, the Ki values for tramadol, its (+) and (-) enantiomers, M1, and its (+) and (-) enantiomers were 17000, 15700, 28800, 3190, 153 and 9680 nM, respectively, compared to 7.1 nM for morphine. These results are consistent with the suggestion of a non-opioid contribution to the clinical profile of tramadol.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8982709     DOI: 10.1016/s0014-2999(96)00770-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  17 in total

Review 1.  The human endogenous metabolome as a pharmacology baseline for drug discovery.

Authors:  Andreu Bofill; Xavier Jalencas; Tudor I Oprea; Jordi Mestres
Journal:  Drug Discov Today       Date:  2019-06-19       Impact factor: 7.851

2.  Suppression of Human Natural Killer Cells by Different Classes of Opioids.

Authors:  Dermot P Maher; Deepa Walia; Nicola M Heller
Journal:  Anesth Analg       Date:  2019-05       Impact factor: 5.108

3.  Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6.

Authors:  Anette Green Nielsen; Rasmus Steen Pedersen; Lene Noehr-Jensen; Per Damkier; Kim Brosen
Journal:  Eur J Clin Pharmacol       Date:  2010-03-31       Impact factor: 2.953

4.  Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy.

Authors:  H Potschka; E Friderichs; W Löscher
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

5.  Tramadol does not enhance sedation induced by acepromazine in dogs.

Authors:  Eduardo R Monteiro; Renan B Lobo; Juarez S Nunes; Julia P P Rangel; Flavia S Bitti
Journal:  Can J Vet Res       Date:  2016-10       Impact factor: 1.310

6.  Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment.

Authors:  William W Stoops; Michelle R Lofwall; Paul A Nuzzo; Lori B Craig; Anthony J Siegel; Sharon L Walsh
Journal:  Psychopharmacology (Berl)       Date:  2012-05-24       Impact factor: 4.530

7.  Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers.

Authors:  Rasmus Steen Pedersen; Per Damkier; Kim Brøsen
Journal:  Eur J Clin Pharmacol       Date:  2006-06-09       Impact factor: 2.953

Review 8.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs).

Authors:  Tania E Perez Jimenez; Katrina L Mealey; Tamara L Grubb; Stephen A Greene; Michael H Court
Journal:  Drug Metab Dispos       Date:  2016-10-06       Impact factor: 3.922

10.  Actions of tramadol on micturition in awake, freely moving rats.

Authors:  Raj Kumar Pandita; Rikard Pehrson; Thomas Christoph; Elmar Friderichs; Karl-Erik Andersson
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.